Xenon Sets March Readout for X-TOLE2 Study, Holds $716M Cash Runway
Xenon Pharmaceuticals reported pro forma cash of $716M after $242.2M ATM proceeds, extending runway into H2 2027. Topline data from the Phase 3 X-TOLE2 study of azetukalner in focal onset seizures is due in early March 2026, with other Phase 3 trials enrolling in epilepsy and MDD by mid-2027.
1. Financial Results and Cash Position
Xenon closed 2025 with $586.0M in cash, cash equivalents and marketable securities, and raised an additional $130.0M in Q1 2026 via its ATM. Total ATM proceeds of $242.2M boost pro forma cash to $716.0M, supporting operations into the second half of 2027 based on current plans.
2. Late-Stage Clinical Pipeline
Topline results from the Phase 3 X-TOLE2 trial of azetukalner in focal onset seizures are expected in early March 2026. Enrollment continues in Phase 3 X-TOLE3 (FOS) and X-ACKT (PGTCS) studies, while X-NOVA2 and X-NOVA3 trials in major depressive disorder and X-CEED in bipolar depression progress toward H1 2027 milestones.
3. Early-Stage Programs
Phase 1 SAD/MAD studies of XEN1701 (NaV1.7) and XEN1120 (KV7) are underway, with data due in 2026 to support Phase 2 proof-of-concept pain studies. IND-enabling work on a NaV1.1 program for Dravet syndrome continues, and the partnered NBI-921355 sodium channel inhibitor is in a Phase 1 epilepsy study with Neurocrine Biosciences.
4. Upcoming Milestones and Investor Events
Following the X-TOLE2 readout, Xenon anticipates an NDA submission for azetukalner in the second half of 2026. An investor call is scheduled around the Phase 3 data release, and additional clinical updates are expected across epilepsy and neuropsychiatry programs through mid-2027.